Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Published Date: 22 Sep 2026

Overall survival favored nivolumab-ipilimumab alone in LONESTAR trial

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Depression risk higher among long-term breast cancer survivors than women without breast cancer history

2.

Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers

3.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

4.

Herpes virus-based vaccine shows promise in targeting tumors without side effects

5.

Ranking of the Best US Hospitals for Psychiatric Care.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot